Business
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
Jonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\nJonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current and future therapeutic areas\n\n\nMark White, MB.ChB, named Chief Medical Officer; Dr. White brings proven track record in late-stage development and commercialization with more than 25 years of experience at AstraZeneca\n\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage. Jonathan Schwartz, M.D., Rocket’s founding Chief Medical Officer, has been appointed to the newly created position of Chief Gene Therapy Officer to expand the Company’s focus on the strategic application of gene therapy technologies to current and future therapeutic areas. In addition, Mark White, MB.ChB, joins Rocket as Chief Medical Officer following more than 25 years at AstraZeneca where he gained deep expertise in late-stage drug development and commercialization across small and large molecules, vaccines and therapeutic areas including rare diseases.\n\n\n“Today’s news represents another exciting and important step forward in our leadership team as we make meaningful strides in our evolution towards commercial stage, adding deep late-stage development expertise and commercial experience to our team along with intensified focus on applying our technologies and successes to date across our pipeline,” said Gaurav Shah, M.D, Chief Executive Officer, Rocket Pharma. “Jonathan’s exceptional scientific and clinical thought leadership will help unlock the full potential of gene therapy platforms for our pipeline and help advance the industry at large. At the same time, I am excited to welcome Mark as CMO who brings an extensive track record of success and deep insight in leading late-stage drug development and execution; he arrives at the perfect time in our growth. Taken together, with Jonathan, Mark and the rest of our exceptionally experienced and talented leadership team, we are well positioned to actively usher in the next stage of Rocket Pharma...